

Neisseria meningitidis Infections (Infectious Disease) - Drugs In Development, 2021

https://marketpublishers.com/r/NF0C8C78CB68EN.html

Date: July 2021

Pages: 105

Price: US\$ 2,000.00 (Single User License)

ID: NF0C8C78CB68EN

Abstracts

Neisseria meningitidis Infections (Infectious Disease) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Drugs In Development, 2021, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections



and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 3, 3, 1, 13, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase 0, Preclinical, Discovery and Unknown stages comprises 2, 1, 2, 2 and 1 molecules, respectively.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neisseria meningitidis Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.



The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.



Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contents

Introduction

Neisseria meningitidis Infections - Overview

Neisseria meningitidis Infections - Therapeutics Development

Neisseria meningitidis Infections - Therapeutics Assessment

Neisseria meningitidis Infections - Companies Involved in Therapeutics Development

Neisseria meningitidis Infections - Drug Profiles

Neisseria meningitidis Infections - Dormant Projects

Neisseria meningitidis Infections - Discontinued Products

Neisseria meningitidis Infections - Product Development Milestones

Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development for Neisseria meningitidis Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Neisseria meningitidis Infections - Pipeline by AIM Vaccine Co Ltd, 2021

Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021

Neisseria meningitidis Infections - Pipeline by Bioworld Technologies Sdn Bhd, 2021

Neisseria meningitidis Infections - Pipeline by CanSino Biologics Inc, 2021

Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021

Neisseria meningitidis Infections - Pipeline by Eubiologics Co Ltd, 2021

Neisseria meningitidis Infections - Pipeline by GlaxoSmithKline Plc, 2021

Neisseria meningitidis Infections - Pipeline by Hilleman Laboratories Pvt Ltd, 2021

Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, 2021

Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, 2021

Neisseria meningitidis Infections - Pipeline by Lanzhou Institute of Biological Products Co Ltd, 2021

Neisseria meningitidis Infections - Pipeline by Neoculi Pty Ltd, 2021

Neisseria meningitidis Infections - Pipeline by Novo Medi Sciences Pvt Ltd, 2021

Neisseria meningitidis Infections - Pipeline by Omvax Inc, 2021

Neisseria meningitidis Infections - Pipeline by Pfizer Inc, 2021

Neisseria meningitidis Infections - Pipeline by ReAlta Life Sciences Inc, 2021

Neisseria meningitidis Infections - Pipeline by Sanofi, 2021

Neisseria meningitidis Infections - Pipeline by Suzhou Weichao Biotechnology Co Ltd, 2021

Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, 2021

Neisseria meningitidis Infections - Dormant Projects, 2021



Neisseria meningitidis Infections - Dormant Projects, 2021 (Contd..1)

Neisseria meningitidis Infections - Dormant Projects, 2021 (Contd..2)

Neisseria meningitidis Infections - Discontinued Products, 2021



List Of Figures

LIST OF FIGURES

Number of Products under Development for Neisseria meningitidis Infections, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021



I would like to order

Product name: Neisseria meningitidis Infections (Infectious Disease) - Drugs In Development, 2021

Product link: https://marketpublishers.com/r/NF0C8C78CB68EN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/NF0C8C78CB68EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970